VLN4 Antibody

What is VLN4 and why is it significant in plant research?

VLN4 (Villin-4) is a plant-specific actin-binding protein that plays critical roles in cytoskeletal organization and dynamics within plant cells. As a member of the villin family, it functions in regulating actin filament bundling, severing, and capping activities that are essential for various cellular processes including cell growth, morphogenesis, and response to environmental stimuli. The significance of VLN4 in plant research lies in its specialized functions in specific plant tissues and developmental stages, particularly in roots, pollen tubes, and trichomes. Understanding VLN4's activity provides crucial insights into plant cell architecture, growth patterns, and stress responses. The anti-VLN4 antibody serves as an invaluable tool for visualizing and quantifying this protein's expression, localization, and dynamics in different plant systems .

What are the optimal storage conditions for VLN4 antibody?

For maximum stability and activity retention of the VLN4 antibody, proper storage conditions are essential. The antibody is typically supplied in lyophilized form and should be stored in a manual defrost freezer to prevent moisture accumulation that could compromise antibody integrity. Critically, repeated freeze-thaw cycles must be avoided as they can lead to denaturation and loss of binding capacity. Upon receiving the shipped product (typically transported at 4°C), it should be immediately transferred to the recommended storage temperature according to the manufacturer's instructions. For long-term storage, aliquoting the reconstituted antibody into smaller volumes before freezing is advised to minimize freeze-thaw cycles during experimental use. Additionally, maintaining proper temperature records and implementing quality control checks before experimental use can help ensure consistent antibody performance across multiple experiments .

Which plant species can be detected using the VLN4 antibody?

The VLN4 antibody demonstrates cross-reactivity with VLN4 proteins across multiple plant species, making it versatile for comparative studies. Based on specificity and cross-reaction profiles, the antibody has confirmed reactivity with Arabidopsis thaliana (the model plant species where VLN4 is extensively studied), Brassica napus (canola), and Brassica rapa. Extended cross-reactivity has been documented for additional species including Gossypium raimondii (cotton), Glycine max (soybean), Solanum tuberosum (potato), Nicotiana tabacum (tobacco), Solanum lycopersicum (tomato), Vitis vinifera (grapevine), Populus trichocarpa (poplar), and even the non-vascular plant Physcomitrium patens. This broad cross-reactivity profile reflects the evolutionary conservation of villin protein structure across diverse plant lineages. Researchers should note that epitope accessibility may vary between species, potentially requiring optimization of fixation and extraction protocols when working with species beyond Arabidopsis .

What are the recommended dilutions for different applications of VLN4 antibody?

When working with VLN4 antibody, application-specific dilution optimization is critical for obtaining specific signals while minimizing background. While standard recommendations provide starting points, researchers should conduct dilution series tests for their specific experimental systems. For immunoblotting (Western blot) applications, initial testing typically begins at 1:1000-1:2000 dilutions in 5% non-fat milk or BSA blocking solution. For immunohistochemistry or immunofluorescence on plant tissue sections, starting dilutions of 1:100-1:500 are recommended, with overnight incubation at 4°C often yielding optimal results. For immunoprecipitation applications, approximately 2-5 μg of antibody per 100-500 μg of total protein extract is suggested. Enzyme-linked immunosorbent assays (ELISA) typically employ dilutions between 1:500-1:5000 depending on the detection system sensitivity. Importantly, each new lot of antibody should undergo validation at multiple dilutions to account for potential lot-to-lot variations in antibody concentration and affinity .

How can I optimize the specificity of VLN4 antibody in tissues with high background?

Optimizing VLN4 antibody specificity in tissues with high background requires a systematic approach to sample preparation and detection protocols. First, implement a more rigorous blocking procedure using 5-10% normal serum from the species in which the secondary antibody was raised, combined with 0.1-0.3% Triton X-100 and 3-5% BSA to block non-specific binding sites. Consider extending the blocking time to 2-3 hours at room temperature or overnight at 4°C. Second, incorporate additional washing steps using PBS-T with increasing stringency (0.1-0.3% Tween-20) between antibody incubations. Third, implement an antigen competition assay by pre-incubating the antibody with purified VLN4 protein or immunogenic peptide (10-100 fold excess) to confirm signal specificity. Fourth, optimize fixation parameters, as overfixation can mask epitopes while underfixation may compromise tissue morphology. For Arabidopsis and related species, 2-4% paraformaldehyde for 15-30 minutes often provides a good balance. Finally, consider using advanced techniques such as tyramide signal amplification or quantum dot conjugated secondary antibodies for improved signal-to-noise ratio in particularly challenging tissues .

What approaches can be used to quantitatively analyze VLN4 antibody binding in plant tissues?

Quantitative analysis of VLN4 antibody binding in plant tissues requires rigorous methodological approaches to ensure reliability and reproducibility of results. A multi-method strategy is recommended. First, implement fluorescence intensity measurements using confocal microscopy with standardized acquisition parameters (laser power, gain, offset, pinhole) and include reference standards in each imaging session. Utilize Z-stack acquisition followed by maximum intensity projections or sum slices for accurate signal quantification. Second, complement imaging data with biochemical quantification through quantitative Western blotting using a standard curve of purified recombinant VLN4 protein. This allows absolute quantification of VLN4 levels in different tissues or treatment conditions. Third, consider flow cytometry analysis of protoplast populations labeled with VLN4 antibody to obtain cell-by-cell quantification data. Fourth, implement automated image analysis pipelines using software like ImageJ/Fiji or CellProfiler with consistent thresholding algorithms to eliminate subjective bias in quantification. Finally, validate findings using orthogonal approaches such as RNA-level quantification (RT-qPCR) or mass spectrometry-based proteomics to correlate antibody-based detection with other measures of VLN4 abundance .

How can next-generation sequencing (NGS) technologies be integrated with VLN4 antibody-based studies?

Integrating next-generation sequencing (NGS) technologies with VLN4 antibody-based studies creates powerful opportunities for multi-dimensional analysis of villin function in plant systems. One approach is to combine chromatin immunoprecipitation (ChIP) with NGS (ChIP-seq) using transcription factor antibodies to identify regulatory elements controlling VLN4 expression across different tissues or stress conditions. Another strategy involves integrating RNA-seq data with VLN4 immunolocalization studies to correlate transcript abundance with protein localization patterns, potentially revealing post-transcriptional regulatory mechanisms. Researchers can also implement Ribo-seq (ribosome profiling) alongside VLN4 antibody-based protein quantification to assess translational efficiency of VLN4 mRNA. For protein interaction studies, proximity-dependent biotin identification (BioID) or APEX2 proximity labeling coupled with mass spectrometry can identify proteins interacting with VLN4 in specific cellular compartments. Analysis of such integrated datasets requires sophisticated computational approaches including clustering algorithms, network analysis, and machine learning methods to identify patterns and relationships. Platforms like Geneious provide tools for analyzing antibody-NGS integrated datasets, allowing visualization of sequence-level variation in VLN4 genes across species that may impact antibody binding specificity .

What are the current challenges in developing AI-assisted approaches for VLN4 antibody optimization?

The development of AI-assisted approaches for VLN4 antibody optimization faces several significant challenges at the intersection of computational biology, immunology, and plant science. First, the limited availability of large, annotated datasets specific to plant antibodies restricts the training of deep learning models that could predict optimal antibody modifications for improved specificity or affinity. Unlike mammalian systems where extensive antibody databases exist, plant-specific antibody sequence-function relationships remain undercharacterized. Second, the complexity of plant cell walls and tissue-specific components creates unique background binding profiles that are difficult to model computationally. Third, current AI approaches struggle with predicting the impact of post-translational modifications (like glycosylation) on antibody performance in plant systems. Fourth, the structural determinants of antibody-antigen interactions in plant proteins like VLN4 have not been sufficiently characterized to inform physics-based AI models. Despite these challenges, emerging approaches combining experimental antibody design with computational modeling show promise. Recent advances in antibody engineering using biophysics-informed models that identify different binding modes associated with specific ligands could potentially be adapted to plant antibody optimization. These models have successfully disentangled multiple binding modes associated with chemically similar ligands and could be applied to enhance VLN4 antibody specificity across different plant species .

How can epitope mapping be used to improve VLN4 antibody specificity across diverse plant species?

Epitope mapping represents a sophisticated approach to enhancing VLN4 antibody specificity across diverse plant species by precisely identifying the antibody-binding regions. A comprehensive epitope mapping strategy begins with in silico analysis of VLN4 sequence conservation across target plant species, identifying regions with high conservation (for broad cross-reactivity) or species-specific domains (for species-selective antibodies). Following computational prediction, experimental validation through peptide array analysis can pinpoint the exact amino acid sequences recognized by the antibody. This involves synthesizing overlapping peptides spanning the VLN4 sequence and assessing antibody binding to each peptide fragment. For conformational epitopes, hydrogen-deuterium exchange mass spectrometry (HDX-MS) or X-ray crystallography of antibody-antigen complexes provides structural insights into binding interfaces. Once epitopes are identified, researchers can design customized immunization strategies targeting conserved epitopes for broad cross-reactivity or species-specific regions for selective detection. Additionally, antibody engineering techniques like site-directed mutagenesis of complementarity-determining regions (CDRs) can enhance specificity for particular epitopes. For challenging species with subtle sequence variations, developing a panel of epitope-specific antibodies enables flexible experimental design. This approach allows researchers to select the appropriate antibody based on their specific experimental requirements and target species .

What controls should be implemented when using VLN4 antibody in immunolocalization studies?

Implementing appropriate controls is crucial for ensuring reliable and interpretable results in VLN4 antibody immunolocalization studies. A comprehensive control strategy should include both positive and negative controls. For positive controls, include wild-type Arabidopsis thaliana tissues known to express VLN4 (such as root hairs or pollen tubes) processed identically to experimental samples. For genetic validation, vln4 knockout/knockdown mutant plants serve as essential negative controls to confirm antibody specificity. Additionally, implement technical negative controls including: (1) primary antibody omission (incubation with secondary antibody only) to assess non-specific secondary antibody binding; (2) secondary antibody controls (using isotype-matched irrelevant primary antibodies) to identify potential cross-reactivity; (3) blocking peptide competition assays where the antibody is pre-incubated with the immunizing peptide to confirm signal specificity; and (4) absorption controls with recombinant VLN4 protein. For cross-species studies, include both evolutionary distant plant species and closely related species to establish specificity boundaries. When possible, complement immunolocalization with orthogonal approaches such as in situ hybridization or VLN4-fluorescent protein fusions to corroborate localization patterns. Finally, implement standardized image acquisition parameters and quantitative image analysis workflows to ensure objective interpretation of immunolocalization data .

What are the optimal fixation and permeabilization methods for VLN4 detection in different plant tissues?

Optimizing fixation and permeabilization methods for VLN4 detection requires tissue-specific adaptations to balance epitope preservation with adequate antibody penetration. For soft tissues like Arabidopsis seedlings, a mild fixation protocol using 4% paraformaldehyde in PBS (pH 7.4) for 30-45 minutes at room temperature preserves VLN4 epitopes while maintaining cellular architecture. For tissues with thick cell walls like mature stems or leaves, increasing fixation time to 1-2 hours may be necessary, potentially with the addition of 0.1-0.2% glutaraldehyde to improve structural preservation. Following fixation, a critical permeabilization step is required, with parameters varying by tissue type. For root tissues, 0.1-0.5% Triton X-100 in PBS for 15-30 minutes typically provides adequate permeabilization. For leaf tissues with waxy cuticles, a higher detergent concentration (0.5-1.0% Triton X-100) or the addition of 1-5% DMSO may improve antibody penetration. For reproductive tissues like pollen or embryos, a combination of 0.3% Triton X-100 with cell wall degrading enzymes (1% cellulase, 0.5% macerozyme) can be effective. In challenging tissues, vacuum infiltration of fixative and permeabilization solutions (3-5 cycles of 5 minutes at 15-20 inHg) significantly improves reagent penetration. For each tissue type, systematically testing a matrix of fixation times, fixative compositions, and permeabilization conditions is essential for optimizing VLN4 detection while preserving tissue morphology .

What troubleshooting approaches can address non-specific binding of VLN4 antibody?

Addressing non-specific binding of VLN4 antibody requires a systematic troubleshooting approach targeting various experimental parameters. First, optimize blocking conditions by testing different blocking agents (5-10% normal serum, 3-5% BSA, 0.5-3% milk powder, or commercial blocking reagents) and extending blocking time to 2-4 hours at room temperature or overnight at 4°C. Second, modify antibody dilution and incubation conditions; diluting the antibody further (1:500-1:5000) and incubating at 4°C for 12-16 hours often reduces non-specific binding while maintaining specific signals. Third, increase washing stringency by adding higher concentrations of detergent (0.1-0.5% Tween-20 or Triton X-100) to wash buffers and extending wash times to 15-30 minutes per wash with at least 4-6 washes. Fourth, pre-absorb the antibody with plant tissue powder from vln4 mutant plants or from non-target species to remove antibodies that bind to common plant epitopes. Fifth, optimize tissue preparation by testing different fixation protocols, as overfixation can increase non-specific binding through epitope masking and protein cross-linking. Sixth, implement antigen retrieval methods such as heat-induced epitope retrieval (HIER) or proteolytic-induced epitope retrieval (PIER) to improve epitope accessibility. Finally, consider using monovalent antibody fragments (Fab) instead of whole IgG molecules to reduce non-specific interactions, particularly in tissues with high endogenous Fc-binding proteins .

How can VLN4 antibody be validated for cross-reactivity with other villin family members?

Validating VLN4 antibody for potential cross-reactivity with other villin family members requires a multi-faceted approach to ensure specificity in experimental applications. Begin with in silico analysis by performing multiple sequence alignments of all villin family proteins (VLN1-5 in Arabidopsis) to identify regions of high sequence similarity that might serve as shared epitopes. Next, implement biochemical validation using recombinant protein technology; express and purify each villin family member (VLN1-5) and perform Western blot analysis with the VLN4 antibody to directly assess cross-reactivity. For higher resolution analysis, create a peptide array containing overlapping peptides spanning all villin family members to precisely map epitope recognition patterns. Genetic validation represents another critical approach; test the antibody on tissues from vln4 knockout plants (negative control) and knockouts of other villin family members to assess signal specificity. Additionally, perform immunoprecipitation followed by mass spectrometry (IP-MS) to identify all proteins pulled down by the VLN4 antibody, which can reveal unintended cross-reactivity. For immunohistochemical applications, compare the localization patterns obtained with the VLN4 antibody against the known expression patterns of other villin family members (from transcriptomic data or reporter gene fusions). Finally, for applications requiring absolute specificity, consider antibody engineering approaches to remove cross-reactive epitopes or develop competitive blocking strategies using peptides corresponding to shared epitopes .

How can VLN4 antibody be effectively employed in super-resolution microscopy studies?

Employing VLN4 antibody in super-resolution microscopy studies requires specific optimization strategies to achieve high-quality nanoscale imaging of villin distribution in plant cells. For Structured Illumination Microscopy (SIM), which provides a resolution of approximately 100-120 nm, standard immunofluorescence protocols can be adapted by using high-quality primary and secondary antibodies with bright, photostable fluorophores such as Alexa Fluor 488, 568, or 647. For Stimulated Emission Depletion (STED) microscopy, which can achieve 30-70 nm resolution, antibody conjugation with STED-compatible dyes like STAR635P or ATTO647N is recommended, with careful optimization of depletion laser power to balance resolution improvement against photobleaching. When implementing Single Molecule Localization Microscopy (SMLM) techniques such as PALM or STORM, which provide 10-25 nm resolution, photoswitchable fluorophores like Alexa Fluor 647 or Cy5/Alexa Fluor 647 pairs should be used with optimized switching buffers containing oxygen scavenging systems and thiol components. Sample preparation requires enhanced fixation protocols using 4% paraformaldehyde with 0.05-0.1% glutaraldehyde to minimize epitope displacement during imaging. For multi-color super-resolution imaging, careful selection of fluorophore pairs with minimal spectral overlap and sequential imaging approaches are necessary to avoid chromatic aberrations. Additionally, implementing drift correction using fiducial markers (such as gold nanoparticles) is essential for accurate image reconstruction. The increased resolution of these techniques enables visualization of VLN4's association with individual actin filaments and its colocalization with other cytoskeletal components at nanoscale precision .

What strategies can be implemented for quantitative co-immunoprecipitation studies using VLN4 antibody?

Implementing quantitative co-immunoprecipitation (co-IP) studies with VLN4 antibody requires rigorous methodological approaches to identify and validate protein interactions while minimizing artifacts. First, optimize antibody coupling by testing different conjugation strategies to magnetic or agarose beads, including covalent crosslinking using dimethyl pimelimidate (DMP) or commercially available conjugation kits to prevent antibody leaching during elution. Second, develop a quantitative IP strategy incorporating SILAC (Stable Isotope Labeling with Amino acids in Cell culture) or TMT (Tandem Mass Tag) labeling for differential proteomic analysis between experimental and control samples. Third, implement stringent controls including IgG isotype controls, vln4 mutant plant extracts, and competitive elution with immunizing peptides to distinguish specific from non-specific interactions. Fourth, optimize extraction and binding conditions by testing different buffer compositions varying in ionic strength (100-500 mM NaCl), detergent types (NP-40, Triton X-100, digitonin) and concentrations (0.1-1%), and stabilizing agents (glycerol, specific protease inhibitors) to preserve physiologically relevant interactions while reducing non-specific binding. Fifth, incorporate crosslinking approaches using cell-permeable crosslinkers like formaldehyde or DSP (dithiobis(succinimidyl propionate)) to capture transient or weak interactions. For validation, implement reciprocal co-IPs when antibodies to interacting partners are available, and complement with orthogonal approaches such as proximity ligation assay (PLA) or fluorescence resonance energy transfer (FRET) in intact plant cells. Finally, analyze resulting mass spectrometry data using specialized software packages that can distinguish true interactors from common contaminants through statistical approaches like SAINT (Significance Analysis of INTeractome) .

How can artificial intelligence approaches enhance VLN4 antibody specificity and application?

Artificial intelligence approaches offer transformative potential for enhancing VLN4 antibody specificity and broadening its applications through several innovative strategies. First, epitope prediction and optimization can be achieved through deep learning models trained on protein structure databases to identify highly specific epitopes within the VLN4 sequence that maximize distinction from other villin family members. These models can incorporate evolutionary conservation data across plant species to predict epitopes that balance species cross-reactivity with paralog specificity. Second, antibody engineering can be enhanced through machine learning algorithms that predict how specific amino acid substitutions in complementarity-determining regions (CDRs) affect binding affinity and specificity. These models can generate virtual antibody libraries for in silico screening before experimental validation. Third, image analysis automation can be implemented using convolutional neural networks (CNNs) trained on immunofluorescence images to automatically identify specific VLN4 localization patterns, quantify signal intensity, and detect co-localization with other proteins across large datasets. Fourth, binding mode prediction can leverage biophysics-informed models to identify distinct VLN4 binding modes associated with specific epitopes, enabling computational design of antibodies with customized specificity profiles. The integration of these AI approaches with high-throughput experimental validation creates a powerful iterative optimization pipeline. Recent advances in projects like the ARPA-H-funded antibody-antigen atlas demonstrate the potential of AI-based approaches to transform antibody development, making it feasible to generate highly specific antibodies against challenging targets like plant villins with reduced time and resource requirements .

What methods can be employed for analyzing VLN4 post-translational modifications using specific antibodies?

Analyzing VLN4 post-translational modifications (PTMs) using specific antibodies requires sophisticated methodological approaches that combine immunological techniques with advanced proteomics. First, identify potential PTM sites through in silico prediction tools and published phosphoproteomic, acetylome, or ubiquitylome datasets specific to plant systems. For phosphorylation analysis, implement a two-pronged approach using general phospho-specific antibodies (anti-phosphoserine, -threonine, or -tyrosine) in combination with the VLN4 antibody for sequential immunoprecipitations. Additionally, consider developing custom phospho-specific antibodies against predicted regulatory phosphorylation sites in VLN4. Second, for detecting acetylation or ubiquitylation, perform immunoprecipitation with VLN4 antibody followed by Western blotting with anti-acetyl-lysine or anti-ubiquitin antibodies. Third, employ mass spectrometry-based validation by conducting immunoprecipitation of VLN4 followed by tryptic digestion and LC-MS/MS analysis with specific enrichment strategies for different PTMs (e.g., titanium dioxide enrichment for phosphopeptides or ubiquitin remnant motif antibodies for ubiquitylation sites). Fourth, implement functional validation of identified PTMs through site-directed mutagenesis of modified residues (to either non-modifiable or modification-mimicking amino acids) followed by in vivo complementation assays. For temporal dynamics studies of PTMs, combine synchronizable plant cell cultures with time-course immunoprecipitation experiments. Finally, for spatial analysis of PTM distributions, develop or source PTM-specific antibodies that recognize specific modified forms of VLN4 for immunolocalization studies in different tissues and under various environmental conditions .

What emerging technologies are likely to enhance VLN4 antibody-based research in the next five years?

The landscape of VLN4 antibody-based research is poised for transformation through several emerging technologies that promise enhanced specificity, sensitivity, and application breadth. First, synthetic biology approaches including cell-free antibody evolution systems and phage display libraries optimized for plant protein recognition will enable rapid development of high-specificity VLN4 antibodies with customized properties. Second, next-generation single-domain antibodies (nanobodies) developed against specific VLN4 epitopes will revolutionize live-cell imaging applications due to their small size (approximately 15 kDa) and superior tissue penetration. Third, expanded multiplexing capabilities through oligonucleotide-tagged antibodies and techniques like CODEX (CO-Detection by indEXing) will allow simultaneous visualization of dozens of proteins in the same plant tissue section, revealing complex interaction networks involving VLN4. Fourth, cryo-electron tomography combined with specific VLN4 antibody labeling will provide unprecedented insights into the three-dimensional organization of actin-villin complexes in near-native cellular environments. Fifth, AI-driven antibody engineering platforms will enable computational design of antibodies with precisely tailored specificity profiles for distinguishing between highly similar villin family members. Finally, the integration of antibody-based detection with spatial transcriptomics will create comprehensive maps linking VLN4 protein localization with local gene expression patterns in complex plant tissues. These technological advances will collectively enable researchers to address fundamental questions about villin function in plant development, stress responses, and evolution with unprecedented resolution and precision .

How might comparative studies of VLN4 across diverse plant species advance our understanding of cytoskeletal evolution?

Comparative studies of VLN4 across diverse plant species using well-characterized antibodies present a powerful approach for investigating cytoskeletal evolution in the plant kingdom. Such studies can reveal how villin structure and function have evolved from early land plants to angiosperms, providing insights into cytoskeletal adaptations accompanying terrestrial colonization and subsequent diversification. A comprehensive research program would begin with systematic immunolocalization studies using validated VLN4 antibodies across representative species from major plant lineages including bryophytes (Physcomitrium patens), lycophytes (Selaginella moellendorffii), gymnosperms (Picea abies), basal angiosperms (Amborella trichopoda), monocots (Oryza sativa), and various eudicot lineages. These studies should focus on homologous tissues and developmental stages to identify conserved and divergent patterns of villin localization. Complementary biochemical analyses can characterize evolutionary changes in villin binding partners through co-immunoprecipitation studies across species, potentially revealing lineage-specific cytoskeletal regulatory networks. Functional studies using heterologous expression of VLN4 orthologs from diverse species in vln4 Arabidopsis mutants can assess functional conservation and specialization. Advanced proteomics approaches can identify evolutionary changes in post-translational modification patterns that might reflect changing regulatory mechanisms. Correlating VLN4 structural and functional diversity with ecological adaptations and growth habits could provide insights into how cytoskeletal regulation contributes to plant adaptation to diverse environments. Finally, integrating these findings with phylogenomic analyses of villin gene family evolution would create a comprehensive evolutionary framework for understanding cytoskeletal evolution across 450+ million years of plant diversification .